Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort.

Jose Miguel Mateos Perez, Carlos Fernandez de Larrea, José Tomás Ortiz, Luis Fernando Quintana, Joaquim Casals, Adriana Patricia Garcia, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, David Moreno, Aina Oliver-Caldes, Alberto Lazaro García, Marta Farrero, Joan Batista Blade Creixenti, Laura Rosiñol Dachs, Maria Teresa Cibeira López

Blood (2025) 146 (Supplement 1): 7494.

https://doi.org/10.1182/blood-2025-7494

Published: 2025

Journal Articles

Multi-omic analysis reveals metabolic fitness of the ARI0002h BCMA CAR T-cell infusion product as a key predictor of clinical outcomes in multiple myeloma

Joan Mañé Pujol, Anna de Daniel, David Moreno, Clara Bueno, Laura Díaz Codony, Aina Oliver-Caldes, Oriol Cardus, Sergi Vaqué Salsench, Natalia Tovar, Helena Llobregat, Marta Español-Rego, Theo Gremen Oliveira, E. Azucena González-Navarro, Manel Juan, Luis Gerardo Rodríguez-Lobato, Anthony Battram, Carlos Fernandez de Larrea

Blood (2025) 146 (Supplement 1): 2294.

https://doi.org/10.1182/blood-2025-2294

Published: 2025

Journal Articles

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

Blood (2025) 146 (Supplement 1): 3983.

https://doi.org/10.1182/blood-2025-3983

Published: 2025

Journal Articles

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3

Alexander Lesokhin, Ruben Niesvizky, Bertrand Arnulf, Sarah Larson, Christopher Strouse, Carlos Fernandez de Larrea, David Vesole, Yuya Nagai, Sharon T. Sullivan, Eric Leip, Andrea Viqueira, Nizar Bahlis

Blood (2025) 146 (Supplement 1): 2269.

https://doi.org/10.1182/blood-2025-2269

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Blood (2025) 146 (Supplement 1): 135.

https://doi.org/10.1182/blood-2025-135

Published: 2025

Journal Articles

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Blood (2025) 146 (Supplement 1): 6192.

https://doi.org/10.1182/blood-2025-6192

Published: 2025

Journal Articles

Longitudinal biomarker dynamics for accurate risk prediction in 464 patients with asymptomatic IgM gammopathy: A spanish multicenter study

Blood (2025) 146 (Supplement 1): 2186.

https://doi.org/10.1182/blood-2025-2186

Published: 2025

Journal Articles

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

Jose Miguel Mateos Perez, Francesc Fernández-Avilés, Maria Teresa Cibeira López, Maria Carmen Martinez Munoz, Carlos Fernandez de Larrea, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Maria Suarez-Lledo, Maria Queralt Salas Gay, David Moreno, Aina Oliver-Caldes, Alberto Lazaro García, Montserrat Rovira, Joan Batista Blade Creixenti, Laura Rosiñol Dachs

Blood (2025) 146 (Supplement 1): 5776.

https://doi.org/10.1182/blood-2025-5776

Published: 2025

Journal Articles

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Blood (2025) 146 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2025-4590

Published: 2025

Journal Articles

CD70-CAR-Ts: a second wind for high-risk myeloma

Luis Gerardo Rodríguez-Lobato, Carlos Fernández de Larrea

Blood (2025) 146 (7): 769–771.

https://doi.org/10.1182/blood.2025029577

Published: 2025

Journal Articles

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Blood (2024) 144 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2024-208083

Published: 2024

Journal Articles

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Blood (2024) 144 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2024-201783

Published: 2024

Journal Articles

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2024-211410

Published: 2024

Journal Articles

Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades

Luis Gerardo Rodríguez-Lobato, Anna De Daniel, Arturo Pereira, Carlos Fernández de Larrea, Natalia Tovar, M Teresa Cibeira López, David F. Moreno, José Miguel Mateos Pérez, Joan Bladé, Laura Rosinol Dachs

Blood (2024) 144 (Supplement 1): 3321.

https://doi.org/10.1182/blood-2024-202549

Published: 2024

Journal Articles

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Beatriz Merchán Muñoz, Alexandra Martínez-Roca, Nuria Ballestar, Cristina Gallego, Nuria Martínez-Cibrián, Valentin Ortiz-Maldonado, Luis Gerardo Rodriguez-Lobato, Nil Albiol, Pilar Ayora, Carla Ramos, Maria Sanchez-Castañon, Manel Juan, Julio Delgado, Jordi Esteve Reyner, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea, Francesc Fernández-Avilés

Blood (2024) 144 (Supplement 1): 7619.

https://doi.org/10.1182/blood-2024-211330

Published: 2024

Journal Articles

The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Blood (2024) 144 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2024-206082

Published: 2024

Journal Articles

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Blood (2024) 144 (Supplement 1): 861.

https://doi.org/10.1182/blood-2024-200277

Published: 2024

Journal Articles

Outcomes of Patients with Relapsed Multiple Myeloma Treated with Pomalidomide, Cyclophosphamide, and Dexamethasone Based on Prior Resistance to Anti-CD38 Monoclonal Antibodies

Marta Hidalgo-Soto, Lucía Martín-Rodríguez, Eugenia Abella Montreal, Inmaculada Fernández-Camacho, Mercedes Gironella Mesa, Yolanda González-Montes, M Teresa Cibeira López, Laura Rosinol Dachs, José Miguel Mateos Pérez, Natalia Tovar, Carlos Fernández de Larrea, Luis Gerardo Rodríguez-Lobato

Blood (2024) 144 (Supplement 1): 6955.

https://doi.org/10.1182/blood-2024-200627

Published: 2024

Journal Articles

Avatrombopag Use in Patients with Persistent Thrombocytopenia Secondary to Intensive Chemotherapy Treatment

Aser Alonso Carballo, Marta Lopez Lopez-Cepero, Maria Jimenez Moya, Sandra Pérez, Lucia García Mañó, Jose Maria Sanchez Raga, Aina Oliver Caldes, Leyre Bento De Miguel, Andres Novo Garcia, Guiomar Puget Juan, Bernat Galmes Sureda, Antonio Palomero Massanet, Carlos Fernández de Larrea, Antonia Sampol Mayol, Mariana Canaro Hinryk

Blood (2024) 144 (Supplement 1): 5445.

https://doi.org/10.1182/blood-2024-210402

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort.

Multi-omic analysis reveals metabolic fitness of the ARI0002h BCMA CAR T-cell infusion product as a key predictor of clinical outcomes in multiple myeloma

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Longitudinal biomarker dynamics for accurate risk prediction in 464 patients with asymptomatic IgM gammopathy: A spanish multicenter study

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

CD70-CAR-Ts: a second wind for high-risk myeloma

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Outcomes of Patients with Relapsed Multiple Myeloma Treated with Pomalidomide, Cyclophosphamide, and Dexamethasone Based on Prior Resistance to Anti-CD38 Monoclonal Antibodies

Avatrombopag Use in Patients with Persistent Thrombocytopenia Secondary to Intensive Chemotherapy Treatment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only